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 List of abbreviations 
 
 
 
AHI: apnoea- hypopnoea index 
APAP: automatic/auto-adjustable CPAP  
APAPfl: APAP guided by detection of flow limitation 
APAPfot: APAP guided by forced oscillation technique 
BiPAP: bilevel positive airway pressure  
BMI: body mass index  
CPAP: continuous positive airway pressure 
EDS: excessive daytime sleepiness  
ESS: Epworth Sleepiness Scale 
FPAP: fixed CPAP pressure 
MAD: mandibular advancement device 
OSA: obstructive sleep apnoea  
OSAS: obstructive sleep apnoea syndrome  
Pmax: maximum positive airway pressure 
Pmean: mean positive airway pressure 
Pmedian or P50: median positive airway pressure 
Ppred: predicted CPAP pressure 
P95: 95th percentile, pressure which is not exceeded during 95% of the time 
PSG: polysomnography 
RCT: randomized cross-over trial 
RERA: respiratory event related arousal 
UARS: upper airway resistance syndrome  
 
  
 
 
I. Introduction 
 
 
 
 
 
 I.1. Obstructive Sleep Apnoea Syndrome 
 
I.1.1. Prevalence 
Obstructive Sleep Apnoea Syndrome (OSAS) is a highly prevalent disease affecting 
millions of people worldwide. Even though it is the most common organic sleep disorder 
causing excessive daytime sleepiness, it is still widely unrecognised an undiagnosed. 
Prevalence data vary remarkably depending on the population under study. The prevalence of 
OSAS is 1-4% according to various cross-sectional studies in the general population, but may 
be more than 4 to 8% between the age of 40 to 59 years (1-6). The different prevalence data in 
these studies can in part be explained by differences in study population. Sleep disordered 
breathing is related to age, gender and body mass index (BMI), and these parameters vary 
among different study populations. Moreover, statistical outcomes are also influenced by the 
way respiratory events are defined.   
 
I.1.2. Definition 
In the early days, the definition of OSAS seemed to be quite simple. An obstructive 
apnoea was defined as a complete upper airway collapse, detected by thermistors. A cessation 
of airflow during at least 10 s, followed by an arousal of at least 3 s, qualified as an apnoea. 
The OSA syndrome was defined as > 5 respiratory events per hour sleep and the presence of 
excessive daytime sleepiness (EDS) (7).  
Over the years, with the development of more sensitive detection methods, e.g. oesophageal 
manometry and nasal pressure cannulae, milder degrees of disturbed breathing were detected. 
Hypopnoea was defined, although rather arbitrarily, as a reduction in airflow of at least 50% 
or a clear reduction less than 50% with an oxygen desaturation of 2-4% and/or an arousal. (7-
9).  
 Moreover, it was recognized that discrete increases in upper airway resistance could 
also result in sleep fragmentation with concomitant clinical symptoms. This led to the 
description of events like flow limitation followed by ‘respiratory event related arousals’ 
(RERA’s), which are implicated in the pathogenesis of the Upper Airway Resistance 
Syndrome (UARS).  
Many attempts have been made to quantify sleep-disordered breathing, hoping this 
would improve the ability to predict and correlate with daytime symptoms. One study by 
Hosselet et al. found that the number of apnoeas, hypopnoeas and flow limitation events best 
predicted sleepiness, but only with a sensitivity of 71% and a specificity of 60% (10). 
Currently, the gold standard to quantify OSAS has remained the apnoea-hypopnoea index 
(AHI), calculated as the sum of apnoeas and hypopnoeas divided by total sleep time (hours). 
 
I.1.3. Clinical presentation and physiological consequences 
Many symptoms of OSAS are non-specific and therefore poor predictors for clinically 
significant disease. Generally, symptoms develop over years and progress with weight gain, 
aging, transition to menopause, alcohol or sedatives use. Frequently, patients are unaware of 
having a medical problem and are referred by their bed partner who complains of snoring or is 
worried about witnessed apnoeas. Snoring is the most frequent symptom of OSAS, occurring 
in 70-95% of patients (11); but is also very prevalent in the general population; 35-45% of 
men and 15-28% of women report habitual snoring (12). Patients themselves complain most 
often about excessive daytime sleepiness, insomnia or unrefreshing sleep. EDS is a 
consequence of the sleep disruption and changes in oxygenation caused by disordered 
breathing. A standard method to quantify subjective sleepiness is the Epworth Sleepiness 
Scale (ESS), a questionnaire asking for the probability of falling asleep in eight well-defined 
circumstances. Neurocognitive dysfunction can show as impaired work performance, 
 concentration or memory deficits or increased rate of traffic accidents (13;14). Personality 
changes such as irritability, anxiety, depression or aggressiveness may be observed. Some 
patients report matinal headaches, dry mouth, nocturia, oesophageal reflux, a sensation of 
choking or dyspnoea (15). 
In general, important differences between subjects may exist in susceptibility of the 
central nervous system to biological effects of sleep-disordered breathing on one hand, and 
perception of symptoms on the other hand. This may explain the imprecise correlation 
between the severity of symptoms and the AHI (16).  
In recent years, it has been proven that OSAS is a risk factor for cardio- and 
cerebrovascular diseases, independent from the association with obesity (17). An increased 
incidence of day- and nighttime hypertension has been reported. Arterial hypertension is 
probably caused by sympathetic overactivity triggered by intermittent hypoxemia, large 
negative fluctuations in intrathoracic pressure and arousal from sleep (18). OSAS has also 
been implicated in the pathogenesis of pulmonary hypertension, nocturnal arrhythmias and 
atherosclerosis (19-22), and has been proven to be an independent risk factor for stroke, 
myocardial infarction, heart failure and metabolic syndrome (23). 
 
I.1.4. Diagnosis 
Although the immense economic burden and the relative simple cure, this disease is 
still widely underdiagnosed. One of the reasons is a general lack of awareness in patients and 
doctors with inappropriate referral, due to lack of training in sleep medicine; another reason 
are the long waiting lists in the diagnostic and therapeutic pathway. 
First of all, the likelihood of OSAS has to be determined by obtaining the history, by 
identifying risk factors and comorbidity and by performing a thorough physical examination. 
 Through the history taking one should also be able to assess the disease severity with the 
impact on quality of life, social and occupational function.  
Nevertheless, clinical assessment alone is not sufficient for the diagnosis of OSAS, 
since none of the current symptoms is specific enough (24). Clinical prediction models have 
been developed to calculate the probability of a patient having OSAS, using symptoms 
combined with anthropometric and demographic data. These prediction models seemed to 
have a high sensitivity (76-96%) but a low specificity (13-54%), and they were not validated 
in populations other than those seen in sleep clinics (15;25;26). 
The gold standard for diagnosis remains in-laboratory polysomnography (PSG) 
attended by a sleep technologist (7;27-29). However, this technique is expensive, labour-
intensive, and the use of different equipment and diagnostic criteria makes it difficult to 
compare PSG data between different labs. The main index obtained from PSG regarding 
OSAS is the AHI, which is however poorly correlated with clinical outcomes such as EDS 
(16). While most research on treatment outcomes was performed in OSAS patients with a 
moderate (AHI > 15/h) to severe (AHI > 30/h) degree, the actual definition also includes mild 
cases (AHI > 5/h) and the presence of excessive daytime somnolence (7). In Belgium, criteria 
for reimbursement of CPAP treatment are an AHI > 20/h and an arousal index > 30/h. 
 
I.1.5. Treatment 
The mainstay for treatment of OSAS is administration of nasal Continuous Positive 
Airway Pressure (CPAP) during sleep, which reverses airway collapse by increasing 
intraluminal pressure, thus providing a mechanical splint that stabilizes the upper airway (30).  
A lot of work has been done to determine which patients would benefit from therapy with 
CPAP. OSAS therapy was primarily aimed at improving quality of life by controlling 
excessive daytime sleepiness. This approach was based on several studies showing that OSAS 
 patients with EDS benefit the most from CPAP therapy with a significant reduction in 
sleepiness assessed with subjective and objective measures. Even in mild OSAS and/or when 
using subtherapeutic levels of CPAP this effect could be demonstrated (31-34). Studies 
performed in asymptomatic patients with severe OSAS could not prove significant clinical 
improvement with CPAP therapy (35). Moreover, CPAP has been shown to have a favourable 
impact on neurocognitive functions, including task performance such as driving simulations, 
memory function or current daily tasks. Even 3-4 hours of CPAP use per night improved 
cognition and daytime vigilance (13;14;36).  
Considering this evidence, the question remained whether asymptomatic patients would need 
treatment. Several studies found that CPAP treatment reduced diurnal and nocturnal blood 
pressure in hypertensive OSAS patients (37-40). Furthermore, favourable effects were seen in 
patients with congestive heart failure. Appropriate treatment resulted in a substantial 
reduction in cardiovascular risk, thus influencing patient mortality (40-44). 
When initiating CPAP, current guidelines advise to perform a full, attended PSG during 
which positive pressure is adjusted in order to determine  the optimal pressure needed for 
maintaining airway patency in all sleep stages and body positions (45). 
Alternative modes of pressure therapy are seldom indicated. Sometimes bilevel 
positive airway pressure (BiPAP) is needed, mostly in patients with reduced chest wall 
compliance or in obesity hypoventilation where high pressures are required in order to 
maintain normal ventilation (45). This technology allows the deliverance of higher pressures 
during inspiration, while expiration is facilitated by lowering the pressure. 
Similarly, there is no convincing evidence that automatic positive airway pressure 
(APAP) is superior for long-term treatment in CPAP-intolerant patients (46-48). In the next 
chapter this item will be further addressed. 
 For those patients who are intolerant to CPAP, mandibular advancement devices 
(MAD) can be considered, especially when apnoeas are caused by pharyngeal narrowing at 
the tongue base. MAD’s can be considered as an alternative treatment only in mild OSAS. 
Therapeutic response is not always predictable and should therefore be confirmed by PSG 
(49;50). 
Over the years, several surgical procedures have been proposed, but there is ongoing 
debate about effectiveness and indications, which seem to be limited to habitual snoring or 
mild OSAS (28;29;51). 
Last but not least, the importance of weight loss should be emphasized in every obese 
patient, either by adjusting lifestyle and diet or by bariatric surgery. In a study performed in 
mildly overweight individuals (BMI < 30), it was stated that a 1% weight change resulted in 
an approximately 3% change in AHI, although the most favourable results were reported in 
morbid obesity (52-54). 
 I.2. The role of APAP in the treatment of OSAS 
 
I.2.1. The gold standard: manual titration 
Ever since Sullivan described CPAP (30), this therapy is still considered the gold 
standard treatment for patients with moderate to severe OSAS. It is widely accepted that 
adequate CPAP pressure has to prevent any degree of upper airway obstruction in all sleep 
stages and body positions, in order to restore normal sleep (55). In general, higher pressures 
are required during REM sleep and in the supine sleep position (56;57). However, the method 
to determine the optimal CPAP pressure is an unsettled subject for debate. For years, the 
standard operating procedure was to perform a full PSG in the sleep lab attended by a sleep 
technician. This allows the technician to manually adjust the pressure as needed and to 
intervene for problems such as mask fitting or leaks. Subsequently, the optimal pressure for 
home treatment is derived from the PSG data obtained throughout the night. It is advised to 
set the final pressure to a level that is sufficient to control sleep-disordered breathing in all 
body postures and sleep stages (55). Considering the higher pressure requirements in REM or 
supine periods, the eventual fixed pressure could be considerably higher than necessary for 
the rest of the night. This higher pressure could increase mask and mouth leaks, pressure 
intolerance and possibly reduce CPAP compliance. An undeniable drawback of this gold 
standard procedure is the lack of an unequivocal and standardized algorithm, resulting in 
considerable intra-technician variability. The procedure is expensive and labour-intensive, 
while most sleep labs have to deal with long waiting lists for diagnostic and therapeutic PSG. 
 
I.2.2. Alternative titration methods 
Because of the mentioned problems accompanying conventional titration, alternative 
CPAP initiation methods were investigated. In order to meet economic considerations, some 
 groups started to perform split-night PSG combining diagnostic and titration PSG in one night 
(58;59), others suggested the use of daytime titration procedures (60).  
Another approach was already suggested in the early nineties of last century by the 
group of Hoffstein. They stated that the optimal CPAP level could be predicted reliably by an 
equation based on three simple and easily available parameters: body mass index (BMI), neck 
circumference, and apnoea/hypopnoea index (AHI) (61). Prospective studies validated this 
equation and found that the predicted pressure (Ppred) ranged within ± 2 cm H2O from 
conventionally determined CPAP. It was suggested that Ppred was a good starting pressure for 
CPAP titration, in order to optimize or shorten manual titration PSG, not to replace it (62-64). 
Hukins found that an “arbitrary pressure” based on BMI alone resulted in similar clinical 
outcomes as manual titration. This was a good starting point for CPAP initiation, allowing to 
select only the compliant patients for a conventional titration PSG (65). Another randomized 
crossover trial compared conventionally determined pressure to Ppred, which the patient could 
adjust at home when needed, and found similar results in efficacy, clinical improvement and 
treatment adherence. They concluded that home self-titration was as efficient as in-laboratory 
manual titration (66). The group of Stradling also promoted an outpatient-based approach to 
initiate CPAP therapy using an algorithm based on neck circumference and OSAS severity 
(number of oxygen desaturation dips > 4 %/h) (67;68). In the end, none of these methods 
were able to undermine the manual titration as the gold standard. 
It was the development of auto-adjustable CPAP devices (APAP), however, that 
brought on a revolution in thought. These "intelligent" devices monitor a combination of 
apnoeas, hypopnoeas, flow limitation or snoring and try to find the ideal pressure by adapting 
the pressure level.  
  
 I.2.3. APAP technology 
Currently, a wide variety of APAP devices has been commercialised. They use 
different methods to detect upper airway obstruction and different algorithms to adapt the 
pressure accordingly. In general, the devices monitor airway vibration (snoring), airflow 
reduction (apnoea or hypopnoea), flow vs. time profile (flow limitation) or impedance with 
the forced oscillation technique. Most devices start at a low baseline pressure (4 cm H2O) and 
gradually increase or decrease the pressure in the presence or absence of respiratory events. 
As a consequence, during wakefulness the pressure can be minimal, while during sleep it will 
slowly adapt according to the degree of upper airway obstruction in all sleep stages and body 
positions. This should allow APAP to constantly deliver the minimum effective pressure, not 
only during one night, but also from night to night.  
APAP devices are used mainly to titrate the fixed CPAP level or to treat the patient at 
home, more seldom they are used as a screening device for identification of OSAS. A titration 
procedure with APAP can occur in attended conditions, allowing the technologist to intervene 
when needed and to titrate several patients at the same time. Performing unattended APAP 
titration at home, however, could reduce waiting lists in the sleep lab and realize cost savings, 
provided that APAP devices are reliable in determining the pressure in unattended conditions 
in a majority of CPAP patients. When using APAP for chronic treatment at home, it is 
suggested that the lower pressure levels could improve patient comfort and eventually 
adherence and compliance (69;70).  
 
I.2.4. APAP performance in research 
At first, studies using APAP in a titration setting compared APAP to conventional 
titration as a method to determine the fixed pressure level for home treatment. They 
concluded that APAP titration was as effective as manual titration since it was equally 
 efficient in lowering the AHI to acceptable levels (AHI <10/hr) in most of the patients studied 
(71-79). Unsuccessful titration was reported in a few patients, mostly due to artefacts such as 
severe mask or mouth leak. In these patients the pressure increased to inappropriately high 
levels due to inappropriate event detection (79).  
After APAP titration, a fixed pressure can be derived for home treatment or APAP 
can be used as a substitute for CPAP in home treatment. Several cross-over trials confirmed 
that both treatment modalities were comparable to conventionally determined fixed pressure 
(FPAP) in terms of respiratory control (as defined above) and impact on sleep quality 
(reduction in arousal index <20/hr and increased slow wave and REM sleep). The same 
results were reported for clinical outcomes showing reduced subjective and objective 
measures of sleepiness (80-96).  
As hypothesized, several studies confirmed that there was a tendency to lower mean or 
median pressure levels with APAP than with conventionally determined FPAP (71;73;75-
78;80-82;92;97). FPAP was mostly 1-2 cm H2O higher but could exceed the mean APAP by 
as much as 6 cm H2O.  
The acceptance of CPAP therapy by patients was similar or even slightly better after 
APAP titration leading to a lower drop out rate in one study (98) and a subjective preference 
for APAP in others (77;81). It was also stated that APAP improved patient adherence and 
compliance since lower pressure profiles offered more patient comfort. Compliance data 
derived from APAP time-loggers over variable periods (2 weeks to 6 months) confirmed a 
tendency to higher APAP usage (77;82;85;87;88;94). Although a larger benefit in compliance 
was expected, previous research had already shown that pressure (in)tolerance was less 
important in this matter. Patient preference and compliance are influenced mostly by 
education and motivation by health care professionals and by treating side effects, more than 
by the characteristics of the machine itself (99-102). 
 Most investigators admitted having difficulties to identify (a subgroup of) OSAS 
patients who would benefit more from APAP than from CPAP. Some found good results in 
those patients with highly variable pressure needs, for example patients with sleep stage and 
body position dependent OSAS (103) or in patients needing high pressure levels (> 10 cm 
H2O) (87).  
As a conclusion to all these optimistic results, several studies stated that APAP was 
safe and efficient as a titration tool and as home treatment, even in unattended conditions 
(81;82;88;94;95;104;105). It was suggested that APAP technology could alleviate the need 
for a titration PSG (106). 
Optimism seemed to be less appropriate when several devices were compared to each 
other in clinical trials. Devices reacted differently or even inadequately to respiratory events 
and a considerable lack of agreement in pressure levels was found (89;107-110). Also, data on 
compliance, patient adherence and preference, were contradictory in several trials and 
predicting factors for better tolerance with APAP remained unclear (86).  
Considering the often contradictory and confusing results obtained by clinical studies, 
another approach to test the performance of APAP devices was mandatory. Bench models 
were developed capable of reproducing realistic and well-defined sleep-disturbed breathing 
patterns. The advantage of bench testing over clinical studies is that inter- and intra-patient 
variability is eliminated. It allows determining whether an APAP device performs adequately 
in detecting respiratory events and in adapting the pressure according to its specific algorithm. 
Bench testing, however, only confirmed the considerable differences in pressure profiles, as 
seen in clinical trials (111-114).  
Recent studies compared the main CPAP initiation methods. Patients were randomized 
to manual titration, unattended APAP titration at home or Ppred with domiciliary adjustment 
when needed (residual snoring or apnoeas) (115). After CPAP treatment for three months, the 
 PSG variables and Epworth Sleepiness Scale showed statistically significant improvement in 
the three groups. The residual AHI under treatment with Ppred was slightly higher, but this was 
not translated to differences in clinical outcomes. Although the APAP group reported more 
side effects, compliance data and dropout rates were similar (115). West et al. compared 
clinical outcomes after home treatment for six months in three groups: 1) APAP, 2) FPAP 
determined after one week of APAP (P95), 3) FPAP determined by a prediction formula. 
Pressure levels were significantly different in the three groups; in particular the P95 group 
received remarkably higher pressures than the two other groups. Nevertheless, subjective and 
objective measures of sleepiness, quality of life scores, but also 24 hour blood pressure were 
similar in all three groups. They concluded that the method of determining CPAP pressure 
makes no significant difference to clinical outcome measures and that the use of APAP has no 
advantage over simpler methods of pressure determination (116). 
 
I.2.5. Limitations of APAP (research) 
A major problem of APAP technology is that manufacturers commercialize devices 
without standardized clinical testing. The designers implement their own proprietary 
algorithms, the detail of which is usually kept undisclosed for commercial reasons. 
Accordingly, the available APAP devices appear as “black boxes” able to modify pressure 
according to rules which are not revealed to the sleep specialist (117).  
Most APAP devices feature an electronic memory that stores pressure data from 
previous use. This information is available to the sleep specialist, who may extrapolate these 
pressure profiles to derive an ‘optimal’ pressure level for subsequent FPAP use. Some 
clinicians select FPAP after visualization of the raw data and eliminate periods of significant 
air leaks (98), others use the P95, being the pressure that is not exceeded during 95% of the 
time. It was shown that the P95 correlated well to a manually determined pressure and was 
 therefore suitable as a fixed pressure for home treatment (74;79;108;118). One of these 
studies, however, demonstrated that the P95 could differ considerably between APAP devices 
(108). In this study there was a bias of 3 cm H2O and a complete lack of agreement between 
the two devices tested (limits of agreement – 3.2 to 9.3 cm H2O), leading to the conclusion 
that unattended automated titration is not reliable enough to replace manual titration.  
The limited information this “black box” provides does not allow checking if false 
events or artefacts are properly identified. Examples of artefacts are coughing, mouth or mask 
leaks, speaking, sighing, swallowing or movements during arousals. These artefacts may 
confuse the operational algorithm and cause inappropriate pressure increases (119). 
Little research was done on safety and side effects of APAP, especially in patients with 
central apnoea or cardiopulmonary disease, since these patients were excluded systematically 
in most trials. Two publications mentioned the occurrence of central apnoeas under APAP, 
increasing when high pressures were applied (120;121). It was reported that the occurrence of 
central apnoeas could activate APAP to perform a pressure increase without resolving the 
events, but, on the contrary, eventually causing more central apnoeas (122). Another fact is 
that patients with lung disease or obesity hypoventilation in association with OSAS may have 
residual oxygen desaturation that could be missed during unattended APAP titration or 
therapy. Thus, the need for treatment with higher pressures, supplemental oxygen or switch to 
BiPAP may be overlooked. 
Most clinical trials used a reduction in AHI < 10/h as a criterion for acceptable 
treatment, although reduction to < 5/h and elimination of airflow limitation could be 
necessary to reverse symptoms like sleepiness in individual patients (123;124). Not all APAP 
devices, however, are able to detect flow limitation. 
Based on these controversial data, a review paper by the American Academy of Sleep 
Medicine recommended the use of APAP titration only in attended conditions since it was 
 found not reliable enough to be used as a substitute for attended CPAP titration. They stated 
that the evidence for and against the premise that APAP treatment would increase acceptance 
and adherence was conflicting (27;47).  
 
 I.3. Aim of the research 
 
When we started to perform clinical trials with APAP, there were no published data 
comparing the effectiveness of different APAP technologies. Whilst most APAP technologies 
seemed to be efficient with respect to lowering the AHI, pressure outcomes differed 
significantly. Moreover, this different performance was not translated into an important 
difference in clinical outcomes. The aim of the present research was to carry out a face-to-
face comparison of different APAP devices in a CPAP titration setting, the hypothesis being 
that different pressure adjustment algorithms can result in different outcomes regarding sleep 
and respiratory variables. 
Our first two randomized cross-over trials (RCTs) compared two APAP devices from 
different manufacturers using different detection methods and algorithms. In the third RCT 
APAP devices were compared operating by the same detection method, but responding with a 
different algorithm. Finally, in order to put on trial the superiority of APAP titration, we 
compared this method to Ppred based on the Hoffstein prediction formula. 
 
 I.4. Materials and methods 
 
I.4.1. Subjects 
The target population were patients diagnosed with OSAS according to Belgian 
criteria for reimbursement of nasal CPAP (i.e. AHI > 20/h and arousal-index > 30/h). After 
the diagnosis of OSA was established, patients were habituated on CPAP treatment at home 
on a pressure level derived from a prediction formula based on BMI, neck circumference 
(NC) and AHI [(0.13*BMI)+(0.16*NC)+(0.04*AHI)-5.12] (61). During follow-up 
consultation after one month it was evaluated whether adjustment was needed based on 
residual symptoms of sleepiness or snoring. After the habituation period a standard overnight 
polysomnography was carried out in the laboratory. The exclusion criteria and reasons for 
drop out are described in the research articles. Patients were asked to participate in the trials 
as they were readmitted to hospital for their titration PSG.  
 
I.4.2. Study design 
In a double blind randomized order, two titration methods were used for each patient 
during the same night using a split-night protocol. Both methods were compared regarding 
their effect on relevant sleep and respiratory variables, and pressure levels were collected 
from the PSG data. The morning after the titration study a subjective evaluation of sleep 
quality was carried out, using a questionnaire and visual analogue scales. In addition, the 
patients were asked to indicate their preference for one of the devices as if they would have to 
choose between them for continued use at home. This subjective preference was compared 
with objective preference, which was defined in terms of better AHI control.  
 
 I.4.3. Sleep studies 
Polysomnography was carried out using a 19-channel digital polygraph (Morpheus™, 
Medatec, Brussels, Belgium). To record airflow, thermocouples plus nasal pressure cannulae 
were used during baseline studies (125). In order to correct for the nonlinearity of the pressure 
signal derived from nasal prongs, the square root was performed on this signal (126). During 
the A-CPAP trial, airflow was evaluated by measuring the respiratory pressure fluctuations in 
the nasal mask, which was connected via 4 mm diameter flexible tubing to the built-in 
manometer (Honeywell 164PC01D37, Freeport, Illinois, USA). This recording closely 
resembles the signal derived from nasal cannulae, and allows reliable detection of apneas, 
hypopnoeas and flow-limitation(127). Respiratory movements were recorded using thoracic 
and abdominal piezo-sensors (Sleepmate™, Midlothian, VA, USA). Respiratory events were 
manually scored according to contemporary guidelines (128). An apnea was defined as a total 
cessation of airflow during at least 10 seconds. For a hypopnoea a decrease of airflow of at 
least 50% was needed, or a clear decrease less than 50% with an oxygen desaturation > 3% 
and/or an arousal. The AHI was calculated as the sum of apneas and hypopnoeas divided by 
total sleep time (hours). Inspiratory snores were manually counted. The snoring-index was 
computed as the sum of inspiratory snores divided by total sleep time (hours). Sleep stages 
were identified according to standard criteria (129). The scoring of arousals was based on 
published guidelines (130). The arousal-index was the sum of arousals divided by total sleep 
time (hours). Sleep stages, respiratory and snoring events, arousals and CPAP levels were 
assessed in epochs of 30 sec. CPAP was determined as the average pressure level over the 30 
sec epoch. 
 
 I.4.4. Functional algorithms and characteristics of the APAP devices  
All APAP’s used in our trials are pro-active devices responding to early indications of 
airway obstruction in an attempt to avoid the occurrence of frank apnoeas or hypopnoeas.  
 
I.4.4.a. Forced oscillation technique (FOT): Weinmann SOMNOsmartTM 
The “forced oscillation technique” is a noninvasive method to measure the upper 
airway impedance in order to quantify and assess the degree of airway obstruction. It consists 
of superimposing a small pressure oscillation on spontaneous breathing through a nasal mask. 
Airflow is measured using a pneumotachograph; resistance is calculated as the ∆P/V ratio. 
Respiratory impedance is derived from pressure and flow signals recorded at the nasal mask, 
and is the resistance to oscillatory flow. During obstructive hypopnoeas the inspiratory 
impedance is intermittently increased, whereas during obstructive apnoeas a permanent 
elevation of the impedance is present. In central apnoeas the impedance is either low (open 
airway) or high (closed airway).  
In the SOMNOsmartTM pressure oscillation is applied with a frequency of 20 Hz and a 
pulse wave of 200µbar. The impedance is calibrated between 0% (nasal mask open to the air) 
and 100% (nasal mask manually occluded). When obstructive apnoeas occur the impedance 
rises to 100%, whereas in central apnoeas the impedance remains at a low level. 
First a five minutes adaptation period is carried out, during which the patient breathes 
quietly through the nasal mask. The device calculates the average impedance, which is 
characteristic to the individual patient. If snoring is detected, the pressure will rise with 0.5 
mbar each 20 seconds, starting after one minute. After this initialization phase slow changes 
in baseline impedance (e.g. nasal congestion) are detected and the individual impedance value 
is continuously adjusted. 
 
 I.4.3.b. Flow limitation 
The respiratory flow-contour is rounded (sinusoidal) in normal unobstructed 
breathing. Upper airway obstruction is heralded by a flattening of the flow-contour in the 
mid-inspiratory portion. The arch of the flow-contour may be quantified by the curvature 
index (c.i.), which is the mid- inspiratory flow calculated as a fraction of the mean inspiratory 
flow. A low curvature-index indicates a high degree of flattening.  
The RESMED AutoSetTM responds differently to various degrees of flattening. 
Severe flattening (c.i. 0.05) will induce pressure increases of 0.2 mbar/tidal volume (± 2 
mbar/min), whereas the pressure will remain unchanged with mild flattening (c.i. 0.15). 
Unobstructed breathing is characterized by absence of flattening (c.i. 0.25), resulting in an 
exponential decline in CPAP using a time constant of 20 minutes. Since snoring is associated 
with a more severe degree of upper airway obstruction, the pressure will be raised with a rate 
of 1 mbar/tidal volume. The mask pressure and the bias flow of the device are also monitored 
by an electronic circuit. When the patient takes of the nasal mask, the flow is automatically 
stopped. Air leak, due to loosening of the mask or opening of the mouth, is represented as 
average flow measured with a low-pass filter (t1/2 20 sec). Autotitration is reliable up to a leak 
of 0.4L/sec. 
The REMstar AutoTM algorithm actively tests for flow limitation instead of 
waiting for it to occur. Two types of tests are performed in order to determine the critical (Pcrit 
test) and optimal (Popt test) pressures. The Pcrit test involves reducing the pressure and 
examining the flow signal for flattening. Pressure is ramped down towards the minimum 
pressure until an increase in flow limitation is detected and the pressure subsequently begins 
to increase. It may ramp down through several pressures to find the critical pressure.  The Popt 
test increases the pressure at a rate of 1 cm H2O every two minutes while the flow signal is 
examined for a reduction in flow limitation. In the absence of improvement the pressure 
 returns to the previous value, in the presence of improvement pressure increases will 
continue. These two tests allow the pressure to be maintained at a level where obstruction is 
not likely to occur, without raising it to unnecessarily high levels.  
During operation the system may be in a testing or non-testing mode. In the testing 
mode, Pcrit and Popt tests will be performed to determine the proper therapeutic pressure. In 
either mode, the system monitors breathing and looks for snoring, apnoeas and hypopnoeas. 
The system will stay in the testing mode for five minutes, or longer if variable breathing is 
detected.  
The ResMed SpiritTM also calculates and delivers the optimal treatment pressure 
by analyzing respiratory airflow data. The pressure is automatically and continuously adjusted 
to the optimal level sufficient to prevent airway obstruction. The system does not differentiate 
between open and closed apnoeas. Response to apnoeas is limited to an increase of the 
pressure to a maximum of 10 cm H2O. However, the device will continue to raise the pressure 
in response to flow limitation and snoring, 
 
  
 
 
II. Research 
 
 II.1. Efficacy of flow- versus impedance guided auto-adjustable 
CPAP: a randomized cross-over trial 
 
Chest 2004; 126(1):25-30  
Pevernagie D, Proot P, Hertegonne K, Neyens M, Hoornaert K, Pauwels R.  
 
 
This paper compared the titration capacity of two APAP devices whose operation is 
based on different modes of sensing incipient upper airway obstruction. Thirty patients were 
included in a double-blind randomized cross-over trial. Using a split-night protocol every 
patient could use both devices during the same night in a randomized order. The AutoSetTM 
uses a pneumotachograph to detect flow limitation of inspired air (APAPfl); whereas the 
SOMNOsmartTM uses the forced oscillation technique (APAP) to measure changes in 
impedance, aiming to keep the resistance below a given percentage of wakefulness values. 
On both APAP devices favourable outcomes had already been reported when studied in an 
attended titration setting and for unattended home treatment. Since it has been shown that 
devices can respond differently to changing pressure demands, we hypothesized that this 
would occur in these two devices running on different detection methods and algorithms.  
This study was designed to compare the titration efficacy of these two APAP technologies in 
terms of effects on sleep quality, respiratory disturbance and snoring indexes. It was also 
evaluated whether the pressure output was appropriate in terms of magnitude and variability. 
APAPfl provided a significantly better control of snoring than APAPfot, and resulted in 
a lower AHI (although not significant). The pressure levels rose significantly with the 
transition from wakefulness to sleep for APAPfl, but fell paradoxically for APAPfot. In 
addition, APAPfot was subject to significantly higher pressure variability. 
 
 
 
 
 
 
 
 II.2. Comfort and pressure profiles of two auto-adjustable positive 
airway pressure devices: a technical report 
 
Respir Med 2003; 97(8):903-908 
 Hertegonne KB, Proot PM, Pauwels RA, Pevernagie DA 
 
 
 In this trial the AutoSetTM and the SOMNOsmartTM were also compared to each 
other, but in terms of subjective tolerance and pressure parameters. For all 50 patients 
included, the overall comfort of both devices was satisfactory. Subjective preference for 
one of both devices was equally divided. The pressure profiles, however, were 
remarkably different. The SOMNOsmartTM produced significantly lower values for P50 
and P95, whereas Pmax values were not significantly different. Interestingly, the AutoSetTM 
pressure profiles correlated significantly better with Ppred than those of the 
SOMNOsmartTM.  
 
 
 
 
 
 
 
 
 II.3. Titration efficacy of two auto-CPAP devices using different 
flow limitation based algorithms 
 
Respiration, in press, e-pub available 
Hertegonne KB, Rombaut B, Houtmeyers Ph, Van Maele G, Pevernagie DA  
 
 
In our previous studies two APAP devices generated similar clinical results but 
remarkably different pressure outcomes and variability, which could be explained by the 
difference in operational characteristics. To substantiate this hypothesis, we compared two 
APAP devices that use a similar detection method, in particular the detection of inspiratory 
flow limitation which proved to perform better in our research. The REMstar AutoTM and 
the ResMed SpiritTM were used in a face-to-face comparison; both operate on flow limitation 
detection, but adapt the pressure according to a characteristic algorithm. This trial was also 
designed as a split-night protocol, in order to allow all 50 patients to use both devices in the 
same night, in a double-blind randomized order.  
Sufficient respiratory control was obtained with both devices, but the AHI was 
significantly lower for the REMstar AutoTM. Remarkably, this result was achieved with 
lower pressure levels. This study also confirms that different APAP performance was not 
translated to differences in subjective evaluation or preference by the patient.  
 
 
 
 
 
 
 
 
 
 II.4. Titration procedures for nasal CPAP: Automatic CPAP or 
prediction formula? 
 
Sleep Medicine, in press, e-pub available 
Hertegonne KB, Volna J, Portier S, De Pauw R, Van Maele G, Pevernagie DA  
 
 
In this trial, two identical REMstar Auto™ devices were used in 45 patients during the 
same night, one operating in the automatic titration mode and one in the fixed mode on 
predicted pressure. The goal of this study was to evaluate whether APAP is superior to a 
prediction formula in assessing the optimal FPAP for home treatment. The primary outcome 
was the AHI; secondary outcomes were pressure profiles and subjective evaluation of sleep 
quality. 
The residual AHI was not significantly different in both treatment conditions, only the 
central apnoea index was higher in APAP than in FPAP mode. The predicted pressure was 
lower than APAP pressure levels and, in terms of bias, corresponded best with Pmean and P50 
of APAP, not with P95. However, there was a lack of precision in all APAP pressure 
categories or a poor agreement between individual pressure levels. There was no difference in 
subjective appreciation and no correspondence between subjective and objective ratings. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
III. Discussion 
 
 DISCUSSION 
 
 
The aim of this research was to carry out a face-to-face comparison of different APAP 
devices in a CPAP titration setting, the hypothesis being that different pressure adjustment 
algorithms could result in different outcomes regarding sleep and respiratory variables. 
In our first two trials, we compared two APAP devices operating on different 
detection methods. We found that the APAPfl (AutoSetTM) achieved lower AHI and snoring 
indices than the APAPfot (SOMNOsmartTM), but only reaching statistical significance for the 
snoring indices. This last device generated a lower average pressure and showed marked 
pressure variability. Both devices differ in algorithm, which determines the speed and amount 
of pressure adjustment. The SOMNOsmartTM shows a steeper slope of adaptation for both 
lowering and increasing the pressure in response to respiratory events, which can explain the 
higher pressure variability. Unfortunately, these fast pressure adjustments are also seen as a 
response to unphysiological signals, e.g. awakenings, leading to high pressure levels at 
inappropriate times. This could explain the inappropriate pressure increase on transition from 
sleep to wakefulness when using the SOMNOsmartTM. The AutoSetTM algorithm, on the other 
hand, allows slower pressure adaptation and is able to compensate for pressure drops due to 
excessive air leakage.  
In order to substantiate our hypothesis that operational characteristics can account for 
different APAP performance, in our third trial we compared two devices that detect flow 
limitation, but are driven by different operational algorithms. The residual AHI was 
significantly lower at lower pressure levels with the use of the REMstar AutoTM compared to 
the ResMed SpiritTM. Again this paradox could be explained by algorithms. The ResMed 
SpiritTM has a steeper slope for increasing than for decreasing the pressure. A delayed 
pressure decrease could lead to overprescription when the pressure is inadequately increased 
 as a response to artefacts. Moreover, pressure-resistance hysteresis may enable faster 
downward than upward titration, and a slow time constant will delay appropriate pressure 
decreases. The algorithm of the REMstar AutoTM, on the other hand, constantly performs tests 
to assess the ‘optimal’ and ‘critical’ pressure, resulting in faster but smaller adjustments. 
When pressure increases are not followed by elimination of the detected events, the device 
will lower the pressure again to its previous level. Eventually, this could result in lower 
effective CPAP levels as found in this trial. 
In our own clinical setting, we initiate OSAS patients on CPAP therapy on a pressure 
determined by the prediction formula of Miljeteig et al. Using this method we obtained a 
favourable clinical response in the vast majority of our patients. Occasionally, the pressure set 
to this predicted level requires slight adaptation on follow-up visits. In the fourth trial, the 
APAP device that performed better in our previous trials, a device detecting flow limitation 
was compared to the fixed, predicted pressure for that patient. Again both methods succeeded 
in obtaining adequate respiratory control, but the APAP pressure levels were significantly 
higher than Ppred. In terms of bias, the Ppred corresponded best with Pmean and P50 of APAP, 
suggesting that the use of P95 as the fixed pressure for chronic treatment could result in 
overprescription. Our findings are in contrast to the APAP literature, in which P95 was 
generally considered suitable as a fixed pressure for home treatment, since it
 
correlated well to 
a manually determined pressure. The observed imprecision of the P95 in our trial could reflect 
random variation in CPAP requirements on one hand, but also intrinsic variability of the 
APAP technology on the other hand. This confirms the need to clarify the validity of P95 
assessment for subsequent FPAP treatment. 
Another finding in this study was that although Pmean and P50 strongly corresponded with Ppred 
(low bias), the correspondence between the individual values was not precise (large variance). 
Considering this poor agreement, Pmean or P50 values cannot be recommended for 
 determining the fixed pressure level for home treatment. The same applies to the P90, P95 and 
Pmax values which, in addition to poor agreement, have a considerable bias to the Ppred. 
In previous research it was stated repeatedly that differences in delivered pressures 
were not paralleled by differences in correcting patients’ sleep-disordered breathing. 
Moreover, proof was never offered that these differences were relevant in terms of (long-
term) clinical outcomes. Our research consistently found a paradox between different APAP 
performance and indifferent subjective evaluation and preference. As stated above, this 
apparent paradox may in part be explained by methodological and design issues. Moreover, 
we hypothesize that there is a margin of pressure tolerance around an optimal CPAP level in a 
given patient at a given time. On one hand, when the pressure is reduced below the critical 
closing pressure of the upper airway, obstructive events will reappear. On the other hand, 
when the pressure is raised above an upper threshold, air leakage or even central events could 
be induced. This conceptual margin of pressure tolerance may amount to several centimetres 
of water. As long as APAP devices, regardless of pressure adjusting methods, operate in the 
presumed zone of pressure tolerance, a substantial control of sleep-disordered breathing will 
be obtained. Especially when the lower threshold (i.e. the critical closing pressure of the 
upper airway) is small, all devices will be efficient. This may explain why only small 
differences between APAP devices can be demonstrated in clinical studies.  
Finally, the results of the present work indicate that, in the majority of patients, it is 
safe to initiate CPAP therapy on a predicted pressure. There seems to be no additional 
advantage in performing an additional APAP titration procedure if patients are stable under 
this pressure, although this hypothesis needs further testing, especially regarding long term 
therapy outcomes regarding cardiovascular and overall mortality. If this could be confirmed 
in long term outcome trials, it could be justified to perform a titration procedure, only in a 
subgroup of patients with residual symptoms. This proposition could have favourable 
 consequences for the huge economic burden of OSAS, but would also increase the diagnostic 
capacities of sleep labs, and in the end promote the quality of patient care. 
  
 
 
IV.   Summary 
    Samenvatting 
 
 SUMMARY 
 
 
 
Since Continuous Positive Airway Pressure (CPAP) was first introduced in the early 
eighties for the treatment of Obstructive Sleep Apnoea syndrome (OSAS), controversy has 
never been cleared on the optimal method to initiate this therapy. A revolution in thought was 
brought about with the development of automatic CPAP (APAP) devices that were, however, 
manufactured and marketed without firm evidence of their added value. Each manufacturer 
designed devices differing in detection method and in pressure adjustment algorithm. The first 
clinical studies emphasized on the equivalent performance of APAP and CPAP in improving 
the apnoea- hypopnoea index (AHI) and sleep quality. It was proclaimed that the added 
advantage of APAP was the possibility to achieve this goal with lower pressures, which was 
hypothesized to promote patient acceptance and compliance.  
The connecting thread in this thesis is face-to-face comparison of different APAP 
devices in a CPAP titration setting, the hypothesis being that different pressure adjustment 
algorithms should result in different outcomes regarding sleep and respiratory variables.  
Our first trials compared devices differing in detection method and algorithm. Both 
devices achieved adequate respiratory control, with only a statistically significant difference 
for snoring. Pressure outcomes differed significantly, which could be explained by the 
operational characteristics of each device. The next step was the comparison of devices 
operating on a similar detection method but with different algorithms. The main outcomes 
were a lower AHI and lower pressure levels for one device, for which again the algorithm 
could account for. Finally, we compared APAP titration to a fixed pressure determined by a 
prediction formula (Ppred). Both methods were equally efficient in lowering the AHI, but the 
fixed pressure was lower than the APAP pressure levels. Moreover, the fixed pressure 
correlated better to the mean (Pmean ) and median (P50 ) APAP pressures (low bias) than to the 
 95th percentile APAP pressure (P95 ), which had been recommended as the preferred pressure 
for home treatment. Another finding in this study was that the correspondence between the 
individual mean and median APAP values was not precise (large variance), so these values 
cannot be recommended for determining the fixed pressure level for home treatment. The 
same applies to the P90, P95 and Pmax values which, in addition to poor agreement, have a 
considerable bias to the Ppred. A consistent finding in all trials was the paradox between 
different APAP performance and similar subjective evaluation and preference. 
Our research subscribes other publications that state that the titration method used is 
not of overriding importance in initiating CPAP therapy. The use of expensive APAP devices 
is not superior to the use of a simple and efficient prediction formula in terms of short term 
clinical outcomes. As long as the selected pressure is situated within a therapeutical margin of 
pressure tolerance around the critical closing pressure of the upper airway, respiratory control 
will be adequate in the majority of patients. From this point of view, we can conclude that 
CPAP therapy can be safely initiated on predicted pressure. If this could be confirmed in long 
term outcome trials, it could be justified to perform a titration procedure, only in a subgroup 
of patients with residual symptoms.  
In our trials the APAP devices used were efficient in obtaining adequate respiratory 
control, but pressure outcomes differed considerably. These differences could be accredited to 
the detection method and the pressure adjustment algorithm a specific device operates on. The 
problem is, however, that the manufacturers do not provide detailed information on the 
algorithms. Our data support the theorem that APAP devices should be submitted to 
standardized clinical and bench testing before commercialization. Moreover, APAP devices 
should no longer be commercialized as ‘black boxes’, the clinician should be provided with 
detailed information on the mode of action of a specific device. 
 
 SAMENVATTING 
 
Sinds de jaren ’80 is ‘continuous positive airway pressure’ (CPAP) via nasale weg de 
hoeksteen in de behandeling van matig tot ernstig obstructief slaapapnoe syndroom (OSAS). 
De optimale CPAP druk zou iedere vorm van slaapgebonden respiratoire belemmering ter 
hoogte van de bovenste luchtwegen moeten voorkomen, niet enkel apnoe’s, hypopnoe’s en 
snurken, doch eveneens ‘flow limitation’. Tot op heden bestaat controverse rond de manier 
waarop men die optimale therapeutische druk bepaalt. Internationaal geldende richtlijnen 
adviseren manuele titratie tijdens polysomnografie, doch een eenduidig protocol voor deze 
procedure werd nooit gevalideerd. 
Als alternatief voor deze arbeidsintensieve titratiemethode werden automatische CPAP 
(APAP) toestellen voorgesteld die in staat zijn op ieder ogenblik de druk aan te passen aan de 
nood van de patiënt. Een breed gamma van dergelijke toestellen werd gecommercialiseerd, 
doch zonder stevig bewijs van hun toegevoegde waarde. Deze toestellen verschillen sterk in 
de manier waarop ze adembelemmering detecteren (de detectiemethode) en in de manier 
waarop ze hierop reageren (het operationeel algoritme). De eerste klinische studies 
benadrukten dat APAP even efficiënt is als CPAP in het verbeteren van de slaapkwaliteit en 
de respiratoire controle. Er werd bovendien gesuggereerd dat de toegevoegde waarde van 
APAP zou liggen in de mogelijkheid om deze objectieven te behalen met lagere drukken, wat 
de aanvaarding en therapietrouw door de patiënt zou bevorderen. 
De rode draad in deze thesis is de rechtstreekse vergelijking van verschillende APAP 
toestellen in een titratieprocedure ter bepaling van de optimale CPAP druk. De hypothese is 
dat verschillende operationele karakteristieken voor adaptatie van de drukprofielen resulteren 
in manifeste verschillen in slaapparameters en respiratoire controle. 
In onze eerste twee studies werden twee toestellen vergeleken met een verschil zowel 
in detectiemethode als in algoritme. Beide methodes slaagden erin de apnoe-hypopnoe-index 
 (AHI) adequaat te doen dalen, doch de meting van ‘flow limitation’ (APAPfl) resulteerde in 
een iets betere respiratoire controle dan de impedantiemeting (APAPfot). De verschillen in 
drukprofielen konden eveneens verklaard worden door de operationele karakteristieken van 
het respectievelijke toestel. De volgende stap was dan ook het vergelijken van twee toestellen 
met dezelfde detectiemethode (APAPfl) doch met verschillende algoritmes. Het ene toestel 
genereerde een lagere AHI en daarenboven lagere drukken, opnieuw te verklaren door het 
specifieke algoritme. Tot slot vergeleken we APAP titratie met een vaste druk gebaseerd op 
een predictieformule (Ppred). Beide methodes resulteerden opnieuw in een efficiënte daling 
van de AHI, doch de vaste voorspelde druk was lager dan de APAP drukken. Daarenboven 
correleerde die vaste druk beter met de gemiddelde en mediane APAP druk (lage bias) dan 
met de 95ste percentiel van APAP, die nochtans in de literatuur aanbevolen werd als de 
optimale druk voor lange termijn behandeling. De individuele waarden van APAP en vaste 
druk daarentegen vertoonden een slechte overeenkomst (grote variantie), zodat de mediane of 
gemiddelde druk evenmin aanbevolen kunnen worden voor het instellen van de behandeling 
thuis. Hetzelfde werd aangetoond voor de andere APAP waarden (90ste en 95ste percentiel en 
maximale druk) die naast deze grote variantie nog een aanzienlijke bias vertonen tegenover de 
Ppred. Ten slotte, een consistente bevinding in al onze studies, was de paradox tussen de 
verschillende performantie van de APAP toestellen en de gelijkwaardige subjectieve evaluatie 
en voorkeur aangegeven door de patiënt. 
Ons onderzoek onderschrijft andere publicaties die stellen dat bij het opstarten van een 
CPAP behandeling de keuze van de titratiemethode niet van doorslaggevend belang is. Met 
betrekking tot klinische resultaten op korte termijn is het gebruik van dure APAP toestellen 
niet superieur ten opzichte van het gebruik van een meer eenvoudige en eveneens efficiënte 
predictieformule. Een adequate respiratoire controle kan bereikt worden in een meerderheid 
van de patiënten op voorwaarde dat de geselecteerde druk zich bevindt binnen een 
 therapeutische marge van druktolerantie rond de kritische sluitingsdruk van de bovenste 
luchtweg. Vanuit dit standpunt kunnen we concluderen dat het veilig is om CPAP therapie te 
starten aan de hand van een predictieformule. Indien dit bevestigd zou worden in 
mortaliteitsstudies, zou men kunnen verdedigen dat enkel in een subgroep van patiënten met 
residuele symptomen het uitvoeren van een titratieprocedure aangewezen is. Dit voorstel zou 
de enorme economische last van OSAS gevoelig kunnen verminderen, maar zou ook de 
diagnostische capaciteit van slaapcentra kunnen verruimen, en uiteindelijk de kwaliteit van de 
patiëntenzorg in het algemeen bevorderen. 
 In onze studies toonden we aan dat alle gebruikte APAP toestellen een adequate 
respiratoire controle bereikten, doch met manifeste verschillen in drukprofielen. Deze konden 
toegeschreven worden aan de detectiemethode en de algoritmes van de specifieke toestellen. 
Het probleem is dat producenten van APAP toestellen om commerciële redenen geen 
gedetailleerde informatie verschaffen over die algoritmes. Onze data ondersteunen de stelling 
dat APAP toestellen dienen onderworpen te worden aan gestandaardiseerd klinisch en 
proefbankonderzoek alvorens wereldwijde commercialisatie. Daarenboven dient het ‘zwarte 
doos’ concept verlaten te worden, gedetailleerde informatie over het algoritme van specifieke 
APAP toestellen moet ter beschikking gesteld worden aan de clinicus.  
 
 
  
V. Future 
perspectives 
 
 Interesting topics for future research emerge from the results of our own studies and research 
from other groups.  
We studied several APAP devices with fundamental differences regarding detection method 
and operational algorithms. All proved to have a beneficial effect on sleep disordered 
breathing, but performed quite differently when compared to each other. As stated above, 
criteria need to be set for standardized clinical and bench testing to which all new APAP 
devices should be submitted in order to prove their efficiency before commercialization.  
It would be interesting to design an APAP device that operates on a combination of different 
indicators for event detection, therefore combining the best of every method.  
In the discussion section, the hypothesis was formulated that a safe margin of pressures 
tolerance exists around the critical closing pressure of the upper airway. This hypothesis could 
be tested by performing a titration polysomnography starting with low pressures and 
repeatedly increasing the pressure after a fixed time.  For every pressure level the residual 
AHI could be calculated, as well as mask or mouth leaks and the pressure under which central 
apnoeas might occur. Thus a pressure-response curve could be determined analogue to 
pharmacodynamic studies.  
Most important, I would like to emphasize that in the last decades many research has been 
performed on the technical performance of APAP devices, but most studies focussed on short-
term outcomes. Large-scale randomised clinical trials should be performed to investigate the 
role of APAP titration and therapy, especially regarding long-term outcomes such as 
cardiovascular morbidity and mortality related to this highly prevalent disease. 
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